08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Mesenchymal precursor cells: Phase III amended

Mesoblast amended a double-blind, placebo-controlled, international Phase III trial evaluating MPCs in chronic CHF patients to change the primary endpoint to recurrent heart failure-related major adverse cardiovascular events (HF-MACE). The previous primary endpoint was time...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Adult stem cells: Phase II data

A U.S. and Australian Phase II trial in 100 patients with chronic moderate to severe lower back pain showed that a single intra-disc injection with 6 or 18 million MPCs each reduced mean VAS scores...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Mesenchymal precursor cells: Phase III start

By year end, Mesoblast said Teva will begin a double-blind, placebo-controlled, international Phase III trial to evaluate a single dose of 150 million MPCs delivered via transendocardial injection catheter to the left ventricle of the...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

Adult stem cells: Phase II start

Mesoblast said in its earnings for 1H13 ended Dec. 31, 2012, that in May it plans to begin a double-blind, placebo-controlled, dose-escalation Phase II trial comparing single IV infusions of 1 and 2 million MPCs/kg...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Mesoblast preclinical data

In sheep with collagen-induced arthritis, a single IV injection of 2 million MPCs/kg led to significant mean reductions compared to saline-treated controls of 88% in IL-6 (p=0.029), 83% in tumor necrosis factor (TNF) alpha (p=0.049),...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

Adult stem cells: Phase II start

On Nov. 8, Mesoblast will begin a placebo-controlled, Singaporean Phase II trial to compare a single intraocular injection of MPCs plus Lucentis ranibizumab vs. Lucentis alone in 18 newly-diagnosed wet AMD patients. Mesoblast gained the...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Clinical News

Adult stem cells: Phase II started

Mesoblast began a double-blind, sham-controlled, Australian and U.S. Phase II trial to evaluate single infections of high- and low-dose MPCs plus hyaluronic acid in 100 patients with chronic low back pain due to lumbar disc...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Clinical News

Adult stem cells: Phase III started

Mesoblast began an international Phase III trial evaluating cord blood expanded with its Revascor mesenchymal precursor cells vs. non-expanded cord blood in 240 patients with hematologic malignancies undergoing unrelated donor bone marrow transplantation. Last year,...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Clinical News

Revascor mesenchymal precursor cells: Interim Phase II data

Interim data from the ongoing, single-blind, placebo-controlled, dose-escalation, U.S. Phase II HF-AB002 trial in 60 patients showed that single injections of 25, 75 and 150 M Revascor plus standard of care (SOC) met the primary...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Angioblast Systems, Mesoblast deal

Mesoblast completed its previously announced acquisition of the 67% of partner Angioblast it does not already own. Angioblast shareholders received 90.8 million Mesoblast shares, which are valued at A$176.2 million (US$176.3 million) based on Mesoblast's...